Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
| Author | :
|
|---|---|
| Abstract | :
Dual BRAF and MEK inhibition produces a response in a large number of patients with stage IV BRAF-mutant melanoma. The existing standard of care for patients with clinical stage III melanoma is upfront surgery and consideration for adjuvant therapy, which is insufficient to cure most patients. Neoadjuvant targeted therapy with BRAF and MEK inhibitors (such as dabrafenib and trametinib) might provide clinical benefit in this high-risk p opulation. |
| Year of Publication | :
2018
|
| Journal | :
The Lancet. Oncology
|
| Volume | :
19
|
| Issue | :
2
|
| Number of Pages | :
181-193
|
| ISSN Number | :
1470-2045
|
| URL | :
https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(18)30015-9
|
| DOI | :
10.1016/S1470-2045(18)30015-9
|
| Short Title | :
Lancet Oncol
|
| Download citation |